Health Technology Assessment (HTA) is increasingly used to evaluate new medicines in order to inform coverage decision making for efficient allocation of healthcare resources. Beyond the traditional regulatory requirements of quality, efficacy and safety, HTA considers the effectiveness, appropriateness and cost of medicinal products and technologies. Pharmaceutical companies are under pressure to adjust their drug development and submission strategy to accommodate both regulatory and HTA requirements for commercial success.
In addition, the variability in HTA organisations and methodologies that are utilised in HTA appraisal and coverage decision-making processes in different countries results in a complex and challenging environment and it is therefore important for companies to incorporate a clear understanding of HTA requirements into early strategic planning to mitigate risk.
As a result of this, CIRS (Centre for Innovation in Regulatory Science) initiated an annual benchmarking project to meet the needs of participant companies for comparative data and information in order to understand and quantify the impact of HTA on clinical development programmes, reimbursement timing and outcomes in different jurisdictions.
This poster summarises the methodology of this long-term benchmarking project, and the preliminary results from 2011-2013 studies.
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Mission
To maintain a leadership role in identifying and applying scientific principles for the purpose of advancing regulatory and HTA policies and processes in developing and facilitating access to medicinal products
Benchmarking the impact of HTA on new medicines development and coverage decision making
Methodology
• Define the performance metrics
The study questionnaire was developed in collaboration with nine multinational pharmaceutical companies to benchmark the HTA process by following individual products. Appropriate performance metrics were agreed upon by all participants to enable meaningful comparison between companies. The questionnaire comprised 19 questions, which related to eight main topics: three topics on the global development of new products and five topics on the roll-out phase in different jurisdictions; Figure 1 illustrates the schematic outline of the questionnaire. Based on the 19 questions, 62 key metrics were collected for each product, which were a combination of both quantitative metrics (for example, milestones) and qualitative indicators (for example, scientific advice activities ).
• Confirm the study scope and criteria
The data collection focused on current products entering into pivotal trials to enable the most up-to-date snapshot of HTA-related activity in clinical development, as well as on licensed products to enable comparison between market access outcomes across jurisdictions. The data was captured separately with the long-term aim of being able to track products through phase III development and across roll-out to multiple jurisdictions over the coming years. The jurisdictional data collection focused on both national level and regional level recommendations for each product. The key jurisdictions included in the study were determined by the study participants: Australia, Canada (national, British Columbia, Ontario), England, France, Germany, Italy (national, Lombardia, Emilia Romagna), Spain (national, Madrid, Catalan) and the USA (CMS Medicare, Wellpoint, United).
• Establish a data collection protocol
To ensure the accuracy, timeliness and security of data collection, an online data collection tool was designed to facilitate the provision of high-quality and comparable data across pharmaceutical companies.
Results
Data on 19 products that entered phase III and 30 products achieving first worldwide regulatory approval from 2009-2012 were collected and analyzed.
•For the phase III projects, 63% received HTA scientific advice, of which 61% occurred during phase II. Company-sponsored advisory boards were the most frequent source of advice as well as the most influential on the development programme. (Figure 2 ) The main reason HTA-related scientific advice was not implemented was due to the prioritisation of regulatory requirements.
•The majority of the phase III projects (69%) included an active comparator in the development plan; the main choice of comparators was "the gold standard comparator for the indication" (Figure 3 ). In addition to inclusion of active comparators, HTA-related requirements were implemented in development programmes. The inclusion of requirements was extremely heterogeneous, with the main requirements being patient-reported outcomes (84%), HTAacceptable endpoints (74%), and cost-effectiveness analysis (74%).
•Additional comparators for local HTA submission were requested by all jurisdictions except the USA (Figure 4 ), the main reasons for requesting additional comparators were "local standard of care" and "least costly therapy". England and France showed the highest percentage of products being reimbursed as per the regulatory label (50% and 55% respectively).
•For licensed products, the median time from regulatory submission to reimbursement decision varied from 639 days (Australia) to 846 days (Italy). For most jurisdictions, there was a gap between the regulatory approval and HTA submission.
Conclusion
Current benchmarking study results show that companies are actively taking scientific advice and incorporating HTA requirements into their development process, although they are still challenged by divergence in HTA processes and requirements across jurisdictions. By continuing to develop this project into 2015 and beyond, the benchmarking database will become more robust and as it matures, could be used as a tool to help companies to achieve greater understanding of the diversity in HTA systems, to make the process more predictable and in particular, to identify and learn from outlier products and HTA reviews.
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Purpose of the study
To give participating companies insight into how HTA requirements are impacting drug development and payer decision making in the context of new medicines being brought to market
Objectives
 Define performance targets to help focus on ongoing performance improvement;  Identify activities and designs through early incorporation into development programmes that best address the HTA needs;  Provide a clear understanding of the HTA systems in various jurisdictions;  Improve the timeliness, transparency, and process predictability of HTA review. 
Top five HTA-related information required for local submission
Contextualise the evidence to local population
Locally relevant economic analysis Sub-group analysis Customized formatted dossier 
Formal indirect comparisons
Australia      Canada      England      France      Germany      Spain      Italy      US United      US Wellpoint       
Example of key questions
• Was HTA-related scientific advice sought and complied with? • When and from whom did company seek advice?
• What was the rationale for the company's choice of active comparator? • What was the timing of the inclusion of HTA requirements? • Did the inclusion of HTA requirements impact the review process, including outcome?
• Was local scientific advice sought and complied with?
• What were the local evidentiary requirements?
• What were the company's expectations of outcomes prior to submission?
• How does time to market access differ between jurisdictions?
• Were multiple submissions required, and if so, at what stage?
• What was the outcome of the coverage decision per region?
• Which requirements were deemed insufficient by the HTA/payer agency?
• Were there any key issues raised during the HTA or coverage decision-making process?
10 questions (28 metrics) 9 questions (34 metrics)
